Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Oct 14 (Reuters) — JCR Pharmaceuticals Co., Ltd.: Jcr Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo™, A Blood-brain Barrier-penetrating Enzyme Replacement Therapy For Hunter Syndrome Jcr Pharmaceuticals Co. - To Seek Marketing Authorization For Izcargo In Mena Region; Taiba To Handle Sales Jcr
JCR Pharmaceuticals received conditional marketing authorization in Kuwait for IZCARGO (pabinafusp alfa) to treat Hunter syndrome, its second approval outside Japan after the UAE.
For best results when printing this announcement, please click on link below: JCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome - This approval follows the recent marketing authorization for IZCARGO™ in the Unite